High oxidative metabolism in tumor cells and the consequent generation of tumor hypoxia is associated with resistance to anti-PD1 and worse clinical outcomes, including decreased PFS, duration of response (DOR), and OS (27). The gene discussed is PDCD1; the disease is neoplasm.